Ultra Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs Humalog® in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)

Author/Address of institution:
Ronnie Aronson1, Helle Linnebjerg2, Jennifer Leohr2, Elizabeth Smith LaBell2, David E Coutant2, Qianyi Zhang2, Thomas Danne3, Robyn Pollom2, Katja Drägert (Non-author Presenter)4
1LMC Diabetes and Endocrinology, Toronto, ON, Canada; 2Eli Lilly and Company, Indianapolis, IN, United States; 3Department of General Pediatrics and Endocrinology/Diabetology at the Children’s Hospital on the Bult, Hannover Medical School, Germany; 4Eli Lilly (Suisse) SA, Switzerland

Background/Introduction:
URLi is a novel insulin lispro formulation developed to more closely match physiological insulin secretion.

Methods:
This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D.

Results:
Onset of insulin appearance was faster with URLi vs Humalog in children (1.1 vs 6.5 min; p=0.0002), adolescents (1.9 vs 6.4 min; p=0.001), and adults (0.9 vs 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs Humalog: 7-fold (p<0.0001) in children, 4-fold (p=0.0003) in adolescents, 5-fold (p<0.0001) in adults; late exposure (AUC3-7h) was reduced by 58% (p<0.0001) in children, 40% (p=0.013) in adolescents, 37% (p=0.021) in adults. Total exposure was similar in URLi and Humalog. At 1h, URLi reduced PPG by 42 mg/dL (p=0.008) in children, 19 mg/dL (p=0.195) in adolescents, 34 mg/dL (p=0.018) in adults, vs Humalog. At 2h, URLi reduced the PPG by 32 mg/dL (p=0.11) in children, 39 mg/dL (p=0.051) in adolescents and was not statistically different in adults, vs Humalog. URLi was well tolerated in all age groups.

Conclusion:
In summary, URLi accelerated insulin lispro absorption, reduced late exposure and early PPG following a test meal vs Humalog in children, adolescents, and adults with T1D.